AI Analysis | Feedback

AI Analysis | Feedback

• PRAX-562 (elizefiban): An investigational therapy in development for rare forms of epilepsy, including SCN2A-DEE and SCN8A-DEE.
• PRAX-944 (ulixacaltamide): An investigational therapy targeting essential tremor, aiming to restore neuronal balance in the brain.
• PRAX-628: An investigational compound being developed as a potential treatment for focal epilepsy.
• PRAX-032: An investigational therapy in early development for the treatment of major depressive disorder.

AI Analysis | Feedback

Praxis Precision Medicines (symbol: PRAX) is a clinical-stage biopharmaceutical company. This means that its drug candidates are currently in various stages of clinical trials and have not yet received regulatory approval (e.g., from the FDA in the U.S.) for commercial sale.

As a result, Praxis Precision Medicines does not currently have major commercial customers in the traditional sense of selling approved pharmaceutical products to wholesalers, pharmacies, or healthcare providers. The company's primary activities at this stage are focused on research, development, and conducting clinical trials to advance its potential therapies toward market approval.

Therefore, there are no specific customer companies or categories of individual customers to list at this time.

AI Analysis | Feedback

AI Analysis | Feedback

Marcio Souza, President & Chief Executive Officer

Mr. Souza has served as a director and President and Chief Executive Officer of Praxis Precision Medicines since April 2020. Before joining Praxis, he was the Chief Operating Officer at PTC Therapeutics, Inc. from May 2017 to April 2020, and its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. Mr. Souza also held positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc., and Sanofi Genzyme Corporation. He has served on the board of directors of Aeglea BioTherapeutics, Inc. since June 2021 and was previously on the board of Clearpoint Neuro, Inc.

Tim Kelly, Chief Financial Officer

Mr. Kelly was appointed Chief Financial Officer of Praxis Precision Medicines in May 2021. He brings over 20 years of experience in the life sciences, pharmaceutical, and biotechnology industries. Prior to Praxis, he served as the chief financial officer and head of corporate management at Foundation Medicine starting in 2019. Before his role at Foundation Medicine, Mr. Kelly spent more than 15 years at the Roche Group, holding various finance positions in product commercialization, pipeline development, manufacturing, and strategic planning.

Alyssa Wyant, Chief Regulatory & Quality Officer

Ms. Wyant is a seasoned executive with over two decades of experience in regulatory affairs and quality management within the biopharmaceutical industry. She currently serves as the Chief Regulatory and Quality Officer at Praxis Precision Medicines, a role to which she was promoted in December 2021. Her background includes leadership roles across multiple organizations, where she has demonstrated a proven track record in navigating complex regulatory landscapes and advancing drug development processes, including at Edge Therapeutics, Inc. and PTC Therapeutics, Inc.

Steven Petrou, Co-Founder & Chief Scientific Officer

Dr. Petrou is a Co-Founder and the Chief Scientific Officer of Praxis Precision Medicines. In December 2021, he decided to dedicate his full time to Praxis after stepping down from his position as institute director of The Florey Institute of Neuroscience and Mental Health.

Megan Sniecinski, Chief Business Officer

Ms. Sniecinski was appointed Chief Business Officer of Praxis Precision Medicines in December 2021. She previously served as the chief business officer at BioCryst Pharmaceuticals, where she oversaw corporate development, program management, and global supply chain. Before BioCryst, Ms. Sniecinski was the senior vice president of business operations and program management at PTC Therapeutics, where she played a key role in program management and business development during the company's transition to a fully integrated and commercial-stage entity. Her experience also includes over a decade at Merck in various operational and strategic roles.

AI Analysis | Feedback

The key risks to Praxis Precision Medicines (PRAX) business include:

1. Clinical Trial and Regulatory Risks: As a clinical-stage biopharmaceutical company, Praxis Precision Medicines' future success is highly dependent on the successful completion of its ongoing clinical trials and obtaining necessary regulatory approvals for its product candidates. Any delays, failures, or adverse safety findings in clinical trials, or regulatory setbacks, could significantly hinder the company's ability to bring its therapies to market, thereby jeopardizing its long-term viability and financial prospects.
2. Financial Sustainability and Need for Additional Capital: Praxis has consistently reported substantial net losses and an accumulated deficit due to significant investments in research and development (R&D). While the company currently has cash reserves, its financial sustainability remains a concern given its high burn rate. There is a risk that Praxis may need to raise additional capital in the future, which could lead to dilution for existing shareholders if new funding is not secured on favorable terms.
3. Product Pipeline Concentration and Risk of Trial Failures: The company's business relies heavily on the success of a limited number of product candidates. Praxis has experienced past setbacks, including a Phase 2/3 study failure for PRAX-114 in major depressive disorder and mixed results for PRAX-944. The failure of any key product candidate to achieve successful clinical endpoints or regulatory approval could significantly impact the company's prospects and investor confidence.

AI Analysis | Feedback

Sage Therapeutics' SAGE-324 for essential tremor is an emerging competitive threat to Praxis Precision Medicines' PRAX-032. SAGE-324, a GABA-A positive allosteric modulator, has reported positive Phase 2 results and is currently in Phase 2/3 development for essential tremor. Praxis's PRAX-032, a T-type calcium channel blocker, is currently in Phase 1 development for the same indication, with Phase 2 trials planned. If SAGE-324 continues to demonstrate strong efficacy and safety and gains regulatory approval significantly ahead of PRAX-032, or proves to have a superior profile, it could establish a dominant market position, severely impacting PRAX-032's commercial potential and competitive viability.

AI Analysis | Feedback

Praxis Precision Medicines (PRAX) is developing several product candidates with the following estimated addressable market opportunities:

• Ulixacaltamide for Essential Tremor (ET): This condition affects approximately seven million people in the U.S.. Analysts estimate a potential peak sales opportunity of $5 billion for ulixacaltamide globally.
• Vormatrigine for Focal Onset Seizures: This indication could generate approximately $1.8 billion in peak sales globally.
• Relutrigine for SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs): These two DEE indications alone are projected to generate up to $1 billion in peak sales globally.

AI Analysis | Feedback

Praxis Precision Medicines (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. The company's future revenue growth over the next 2-3 years is expected to be driven by the advancement and potential commercialization of its pipeline assets and strategic collaborations.

1. Regulatory Approval and Commercial Launch of Ulixacaltamide for Essential Tremor (ET): Praxis successfully completed its Phase 3 program (Essential3 studies) for ulixacaltamide in treating Essential Tremor, with both studies meeting their primary endpoints and demonstrating significant improvements in patient symptoms. The company has scheduled a pre-New Drug Application (NDA) meeting with the FDA for Q4 2025, with plans to submit its first NDA soon. Analysts project a substantial market potential for ulixacaltamide, with some forecasting "blockbuster status by 2028."

2. Progression and Potential NDA Submission of Relutrigine for SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs): Praxis reported positive top-line results from the Phase 2 EMBOLD trial of relutrigine in SCN2A and SCN8A-DEEs. Following comprehensive discussions with the FDA, Praxis plans an interim analysis of the EMBOLD study in Q1 2025, which, if successful, could support an NDA submission in early 2026. The company is leveraging its Breakthrough Therapy Designation for relutrigine to accelerate its development.

3. Advancement of Vormatrigine through Clinical Trials for Focal Onset Seizures: The company has completed recruitment for the POWER1 study of vormatrigine in focal onset seizures, with topline results anticipated in the first half of 2026. The POWER2 study is also underway, with enrollment expected to be completed in the second half of 2026, marking further progress toward potential future commercialization.

4. Pipeline Expansion and Strategic Partnerships: Praxis continues to develop a robust pipeline of clinical-stage product candidates for CNS disorders, utilizing its proprietary Cerebrum™ and Solidus™ platforms. Historically, the company has generated revenue through collaboration agreements, which can include upfront payments, milestone payments, and royalties on future sales. While the KCNT1 program was in-licensed by UCB in December 2024, leading to a decrease in collaboration revenue for Praxis, future strategic partnerships based on other pipeline assets could serve as significant revenue drivers.

AI Analysis | Feedback

Share Issuance

• In October 2020, Praxis Precision Medicines completed its initial public offering (IPO), raising aggregate gross proceeds of $218.5 million.
• In September 2025, Praxis terminated a 2024 at-the-market (ATM) equity offering program with Jefferies LLC, through which it had sold 1,368,176 shares for approximately $86.2 million in gross proceeds. Concurrently, the company entered into a new ATM equity offering program with TD Cowen to offer and sell shares of common stock with an aggregate offering price of up to $250 million.
• In October 2025, Praxis announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expecting to generate approximately $525 million in gross proceeds from the sale of 3,025,480 shares of common stock and pre-funded warrants to purchase up to 318,470 shares. The net proceeds from this offering were approximately $567.0 million.

Inbound Investments

• Praxis Precision Medicines launched in May 2020 with $100 million in financing supported by Blackstone Life Sciences and Novo Holdings.
• As of September 30, 2025, Praxis had $389.2 million in cash, cash equivalents, and marketable securities. This, combined with the net proceeds from the October 2025 public offering, is anticipated to fund operations into 2028.

Capital Expenditures

• Praxis Precision Medicines reported capital expenditures of $0.06 million in 2024.
• For the three months ended March 2025, capital expenditures were $64,000.
• Research and development expenses, a significant component of operating expenditures, were $65.8 million for the three months ended September 30, 2025, an increase of $23.9 million from the same period in 2024, primarily driven by investments in its Cerebrum™ and Solidus™ platforms.